Review| Volume 18, ISSUE 3, P301-306, March 2016

Download started.


Technological developments for small-scale downstream processing of cell therapies


      Despite considerable regulatory and clinical hurdles, the development and use of cell-based therapies are gaining momentum. As more of these therapies move toward commercial approval and larger-scale distribution, associated manufacturing and processing technologies are being advanced. Modern technologies directed at downstream processing seek to distribute such therapies from the manufacturing site to the patient more efficiently and reliably. Novel small-scale downstream solutions boost the transformation of cell therapies from abstraction to reality.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Alliance for Regenerative Medicine
        Regenerative Medicine Annual Report.
        (accessed 20.02.15)
        • MarketsandMarkets
        Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System)—Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020.
        (accessed 20.02.15)
        • IBIS World
        Cell Therapy in the US: Market Research Report.
        (accessed 20.02.15)
        • McAllister T.
        • Audley D.
        • L'Heureux N.
        Autologous cell therapies: challenges in US FDA regulation.
        Regen Med. 2012; 7: 94-97
        • Malik N.
        Allogeneic versus autologous stem-cell therapy.
        BioPharm Int. 2012; 25 (accessed 19.03.15)
        • Hourd P.
        • Chandra A.
        • Medcalf N.
        • Williams D.J.
        Regulatory challenges for the manufacture and scale-out of autologous cell therapies.
        in: StemBook. Harvard Stem Cell Institute, Cambridge (MA)2008 (2014)
        • Pattasseril J.
        • Varadaraju H.
        • Lock L.
        • Rowley J.
        Downstream technology landscape for large-scale therapeutic cell processing.
        BioProcess Int. 2013; 11: 46-52
        • Yokoyama W.M.
        • Ehrhardt R.O.
        Cryopreservation and thawing of cells.
        Curr Protoc Immunol. 2012; Appendix 3: 3G
        • Dijkstra-Tiekstra M.J.
        • Setroikromo A.C.
        • Kraan M.
        • Gkoumassi E.
        • de Wildt-Eggen J.
        Optimization of the freezing process for hematopoietic progenitor cells: effect of precooling, initial dimethyl sulfoxide concentration, freezing program, and storage in vapor-phase or liquid nitrogen on in vitro white blood cell quality.
        Transfusion. 2014; 54: 3155-3163
        • Burdon D.W.
        Issues in contamination and temperature variation in the cryopreservation of animal cells and tissues.
        Revco Technol Appl Note. 1999; : 99-108
        • Thompson M.
        • Tang Q.
        • Schryver B.
        • Ehrhardt R.
        Validation of a novel portable freezing device in the optimal freezing of peripheral blood mononuclear cells for potential cell therapy use.
        Cytotherapy. 2014; 16: S29
        • Foussat A.
        • Rietze R.
        • Pottier E.
        • Schryver B.
        • Thompson M.L.
        • Ehrhardt R.O.
        Effective cryopreservation and recovery of human regulatory T-cells.
        BioProcess Int. 2014; 12: 34-38
        • Hanslick J.L.
        • Lau K.
        • Noguchi K.K.
        • Olney J.W.
        • Zorumski C.F.
        • Mennerick S.
        • et al.
        Dimethyl sulfoxide (DMSO) produces widespread apoptosis in the developing central nervous system.
        Neurobiol Dis. 2009; 34: 1-10
        • Fritsch G.
        • Witt V.
        • Matthes S.
        • Dworzak M.
        • Artwohl M.
        • Clarke D.
        • et al.
        Improved post-thaw stability validation of peripheral blood cell products utilizing the intracellular-like CryoStor® Cryopreservation Solution, and Preliminary Results of Clinical Application.
        (accessed 10.05.15)
        • BioLife Solutions
        Use of CryoStor® in Clinical Trials of New Regenerative Medicine Products & Therapies.
        (accessed 10.05.15)
        • BioCision, LLC
        Ultra-Low Temperature (ULT) Handling and Transport.
        (accessed 20.02.15)
        • BioCision, LLC & Brooks Automation, Inc
        The CryoPod Carrier System [press release].
        (May 5)2015
        • Loretz L.J.
        • Li A.P.
        • Flye M.W.
        • Wilson A.G.
        Optimization of cryopreservation procedures for rat and human hepatocytes.
        Xenobiotica. 1989; 19: 489-498
        • Mazur P.
        • Leibo S.P.
        • Farrant J.
        • Chu E.H.Y.
        • Hanna M.G.
        • Smith L.H.
        Interactions of cooling rate, warming rate and protective additive on the survival of frozen mammalian cells.
        in: Wolstenholme G.E.W. O'Connor M. Ciba foundation symposium—the frozen cell. John Wiley & Sons, Ltd, Chichester, UK1970
        • BioCision, LLC
        ThawSTAR™ Automated Cell Thawing System.
        (accessed 20.02.15)
        • Raviv L.
        Bringing cell therapy up to patient bed side—the development of an automated and controlled point of care cell thawing device. Presentation.
        Engineering Conferences International: Scale-Up and Manufacturing of Cell-Based Therapies IV. 2015 (San Diego, CA, USA)
        • US Food and Drug Administration
        Current Good Tissue Practice and additional requirements for manufacturers of human cells, tissues, and cellular and tissue-based products.
        (accessed 20.02.15)
        • Trainor N.
        • Pietak A.
        • Smith T.
        Rethinking clinical delivery of adult stem cell therapies.
        Nat Biotechnol. 2014; 32: 729-735